Napo Pharmaceuticals

news

December 23, 2008
Napo Announces Publication of Paper on Crofelemer for Indication of Irritable Bowel Syndrome

December 10, 2008
Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals

October 16, 2008
Cancellation of Listing

October 15, 2008
Fundraising

October 3, 2008
Fundraising

September 25, 2008
Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrheal Diseases (Subject to FDA Approval)

September 22, 2008
Napo Announces Positive Clinical Data Indicating Crofelemer Could Effectively Treat Cholera

September 19, 2008
Novel Drug Development Alliance Between Napo Pharmaceuticals and Direct Relief International Targets Global Implications of Pediatric Diarrhea

September 18, 2008
Results of Special Meeting of Stockholders

September 15, 2008
Fundraising

September 5, 2008
Proposed delisting and cancellation of the Company's Listing and posting of a Circular and Notice of Special Meeting of Shareholders

September 5, 2008
Proposed Cancellation of Listing of Common Shares on the Official List Amendment of Bylaws Amendment of Certificate of Incorporation Authorization of Reverse Stock Split

August 28, 2008
Interim Results for the Six Months Ended 30 June 2008

July 10, 2008
Review of Existing Phase 2 Trial Data Indicates Positive Effect on Pain-Discomfort-Free Days in Patients with Diarrhea Predominant Irritable Bowel Syndrome treated with Crofelemer

July 1, 2008
Total Voting Rights and Share Capital

June 27, 2008
Issuance of US$0.12 Million Convertible Notes

June 23, 2008
US $2.1 million fundraising and update on partnership discussions

May 9, 2008
Napo presents at ISPOR meeting in Toronto

May 7, 2008
Napo RSA Announcement

May 7, 2008
Share Purchase

April 30, 2008
Napo Pharmaceuticals, Inc. 2007 Annual Report

April 30, 2008
Napo Annual Report and Accounts

April 25, 2008
Share Purchases

April 24, 2008
Share Purchase

April 21, 2008
Share Purchase

April 21, 2008
Interim Management Statement

April 17, 2008
Results for the Year Ended 31 December 2007

April 10, 2008
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

March 13, 2008
Admission to CREST

March 5, 2008
$2.55 Million Fundraising by Way of Issue of Convertible Debt and Common Shares and $1.5 million Extension of Payment Terms with Certain Trade contractors

February 28, 2008
Napo Licenses Patent from University of Iowa Research Foundation for Secretory Diarrhea

February 19, 2008
Block Listing Six Monthly Return

February 11, 2008
Termination of Trine Agreement
Napo now in active discussions for commercial partner for crofelemer

February 6, 2008
Napo Receives Enteric Coated Formulation of Crofelemer Patent from United States Patent Office

February 4, 2008
Napo Appoints Dr. Jerome Ernst as Clinical Science Advisor

January 7, 2008
Issue of Convertible Promissory Notes

If you would like to receive e-mail alerts when we send out press releases, please send an e-mail to news@napopharma.com with the subject 'subscribe'.